Hello, welcome to visit!

Consultation hotline


Future development prospects

发布时间:2021-06-23 14:50:49浏览次数:

1. The demand of global pharmaceutical market continues to grow

Since 2000, the growth rate of the global generic drug market has caught up with and surpassed that of the global pharmaceutical market. In the next few years, the growth rate of the generic drug market will continue to maintain a high level and become the main driving factor for the growth of global pharmaceutical expenditure, especially in the emerging pharmaceutical market. In the next 5-10 years, generic drug market will maintain a high growth rate and become an important growth pillar of global pharmaceutical market, especially in developing countries.

2. Global transfer of pharmaceutical intermediates and APIs

Driven by the rapid development of the global pharmaceutical market, in the context of fierce drug price competition, for the sake of cost control, the API and pharmaceutical intermediates industry has the need to transfer to developing countries with cost advantage. China, India and other developing countries have become the key regions to undertake the global transfer of API due to their good technical base of API and intermediate. The above cost advantages of Chinese enterprises, together with the relatively mature domestic basic chemical industry and labor supply, as well as the complete set of conventional pharmaceutical equipment, constitute the core force of China's API and pharmaceutical intermediates industry to participate in the global market competition.

3. The support of national industrial policy

Pharmaceutical industry is an important part of China's national economy, and closely related to people's health. It is an important industry related to the construction of a harmonious society. In recent years, the state has taken a number of measures to encourage and promote the healthy development of China's pharmaceutical industry. Many policies clearly point out that, guided by demand, we should encourage the imitation of clinically necessary, effective and short supply drugs, encourage the imitation of drugs needed for the prevention and treatment of major infectious diseases and rare diseases, promote enterprises to strengthen the research and development of pharmaceutical raw and auxiliary materials and packaging materials, use new materials, new processes and new technologies, and improve the quality level.